HepaRegeniX GmbH is a Tuebingen, Germany–based clinical-stage biopharma developing orally available small-molecule therapies that stimulate rapid liver regeneration. Its lead candidate, HRX-215, selectively inhibits MKK4 and is being developed to prevent post-hepatectomy liver failure, enable transplantation with smaller living donor grafts, and treat severe alcohol-associated hepatitis. HRX-215 is currently in a combined Phase Ib/IIa trial, and the company plans to use new funding to complete Phase Ib and advance the Phase IIa study. Beyond HRX-215, HepaRegeniX is developing HRX-233 to overcome kinase inhibitor resistance in KRAS-driven tumors. The company is led by CEO Elias Papatheodorou and has demonstrated safety of HRX-215 in clinical trials to date. HepaRegeniX raised €21.5M to support these clinical development milestones. HepaRegeniX is developing novel regenerative therapies targeting acute and chronic liver diseases based on inhibition of Mitogen-Activated Protein Kinase Kinase 4 (MKK4). The company has discovered multiple drug candidates centered on this proprietary molecular target. Its lead candidate, the MKK4 inhibitor HRX-215, recently completed Phase 1 clinical testing. HepaRegeniX intends to use the new funding to advance the clinical development of HRX-215. The company operates from Tuebingen, Germany and focuses on unlocking hepatocyte regenerative capacity even in severely diseased livers by suppressing MKK4. Recent financing strengthens its runway for upcoming clinical work. HepaRegeniX is a preclinical-stage company focused on developing a novel therapy for acute and chronic liver diseases. The company’s lead approach targets Mitogen-Activated Protein Kinase 4 (MKK4), a key regulator of liver regeneration. Suppression of MKK4 is reported to unlock the regenerative capacity of hepatocytes even in severely diseased livers. The therapeutic concept was discovered by Prof. Lars Zender and his research group at the University Hospital Tübingen. Led by CEO Dr. Michael Lutz, HepaRegeniX has discovered and developed several preclinical drug candidates based on this proprietary molecular target. The company closed an over €11M Series B and intends to use the funds to advance its MKK4 inhibitor into clinical testing later in 2020. HepaRegeniX GmbH is developing a therapeutic approach targeting liver regeneration by inhibiting MKK4. The company has acquired worldwide exclusive rights to the related IP discovered by Prof. Lars Zender and his research group at the University Hospital Tübingen. In collaboration with the Zender group and the medicinal chemistry group of Eberhard‑Karls University of Tübingen, HepaRegeniX has identified its first small‑molecule MKK4 inhibitors. The company plans to use the Series A proceeds to advance medicinal chemistry discovery programs and preclinical development of drug candidates through IND filing. Management, led by CEO Dr. Wolfgang Albrecht, is targeting a first clinical study for the treatment of acute liver failure in 2019. The company completed a €9m Series A financing to fund these efforts.

Total raised

$63M

Funding rounds

4

Latest round

Equity

Latest activity

Apr 2025